In The Spotlight

Shares of Nurix Therapeutics Inc. (NRIX) are down 37% from their all-time high of $52.38, set on Dec.14, and trade around $32.

Investing in shares is a risky business, but there are some stocks that never disappoint. Zoetis Inc. (ZTS) is one of them.

Shares of Fulcrum Therapeutics Inc. (FULC) have lost nearly 19% year-to-date and trade around $9.

Synthetic lethality provides a new opportunity in oncology drug development. First described by Calvin Bridges in 1922, synthetic lethality arises when deficiencies in a pair of genes occur simultaneously to result in cell death, but if that deficiency exists in only one gene, the cell will survive.

Breast cancer is said to be the second most common cancer in women after skin cancer. As of January 2021, there were over 3.8 million women with a history of breast cancer in the U.S., according to BreastCancer.org. Estrogen receptor-positive (ER-positive) breast cancer accounts for 78% of the breast cancers.

Syros Pharmaceuticals Inc. (SYRS), a biopharmaceutical company developing medicines that control the expression of genes to treat cancer and genetic diseases, has a couple of clinical trial milestones to be achieved this year.

Shares of Longeveron Inc. (LGVN), which recently debuted on the NASDAQ, have halved in value over the past three months to trade around $5.

Given the rising number of daily coronavirus cases in some countries, the emergence of new variants, and waning immunity, it is for sure that COVID-19 will be an ongoing global public health concern. As of this writing, 155.3 million cases have been reported across the world, with the death tally crossing 3.24 million.